Immune Cells Studied in Type 1 Diabetes Through Sample Collection
Researchers collect biological samples to study immune cells involved in type 1 diabetes development.
Key facts
- Who runs it
- Institut National de la Santé Et de la Recherche Médicale, France
- Where
- Bobigny, Bondy, Colombes, Corbeil-Essonnes, Le Chesnay, Le Kremlin-Bicêtre, Paris, and Pontoise, FranceSee the 17 sites
- Trial code
- Registry title
- BeAT1D: Benign Autoimmunity and Type 1 Diabetes
- Status
- Recruiting
- People taking part
- 1,160 people, planned
- Started
- 24 Oct 2022
- Expected to end
- Apr 2030
- Type of study
- Observational, 4 groups
- Treatments tested
- Biosampling
- Record updated
- 22 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with type 1 diabetes, people with other forms of diabetes or autoimmune hormone disorders, and people without diabetes. A fourth group is having abdominal surgery with planned removal of pancreatic lymph nodes.
- Age
- From 1 year old. No upper limit is stated.
- Sex
- All sexes can join.
- Disease stage
- Type 1 diabetes: high blood sugar with insulin started within 6 months of the first symptoms, and/or at least one anti-islet auto-antibody.
- Biomarker or test result
- For type 1 diabetes: at least one anti-islet auto-antibody can be used instead of the insulin criterion.
Main reasons for not taking part
- Pregnancy at the time of joining
- Known HIV or HCV infection
- No social security coverage
- Placement under judicial protection
- No signed informed consent
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Type 1 diabetes: type 1 diabetes, as defined by hyperglycemia and long-term insulin therapy started within 6 months from clinical onset; and/or the presence of at least one anti-islet auto-antibody
- Other forms of diabetes or autoimmune endocrinopathy: other forms of diabetes (e.g. type 2, ketosis-prone, familial, secondary, immunotherapy-induced diabetes); and/or other autoimmune endocrinopathies, isolated or multiple
- No diabetes: absence of diabetes or impaired glucose tolerance; absence of tumor, infectious or immune pathologies, or other conditions related to autoimmune or metabolic alterations that may bias the variables under study
- Lymphadenectomy planned in the frame of an abdominal surgery: pancreatic lymphadenectomy planned at the occasion of an abdominal surgery for the treatment of an underlying condition
Who cannot take part
- For all participants: ongoing pregnancy; known HIV/HCV infection; absence of social security coverage; placement under judicial protection; absence of signature of the informed study consent
Where in France
- APHP - Hôpital AvicenneBobigny, FranceContact: Emmanuel Cosson, MD PhDNot yet recruiting
- APHP Hôpital J. VerdierBondy, FranceContact: Nadine Lucidarme, MDNot yet recruiting
- APHP Hôpital L. MourierColombes, FranceContact: Stéphanie Gréteau-Hamoumou, MDNot yet recruiting
- Hôpital Sud FrancilienCorbeil-Essonnes, FranceContact: Alfred Penfornis, MD PhDNot yet recruiting
- Hôpital Mignot - Service de PédiatrieLe Chesnay, FranceContact: Catherine Ajzenman, MDNot yet recruiting
- Hôpital Mignot - Services de Diabétologie/Endocrinologie AdultesLe Chesnay, FranceContact: Jean-Paul Beressi, MDNot yet recruiting
- APHP Hôpital Kremlin-BicêtreLe Kremlin-Bicêtre, FranceContact: Cécile Petit-Bibal, MDNot yet recruiting
- Aphp - Hopital BichatParis, FranceContact: Ronan Roussel, MD PhDNot yet recruiting
- APHP - Hôpital Saint AntoineParis, FranceContact: Bruno Fève, MD PhDNot yet recruiting
- APHP Hôpital Cochin - Service de ChirurgieParis, FranceContact: Pierre-Philippe Massault, MDNot yet recruiting
- APHP Hôpital Cochin - Service de Diabétologie et Immunologie CliniqueParis, FranceContact: Etienne Larger, MD PhDTaking people
- APHP Hôpital Européen G. PompidouParis, FranceContact: Alina Radu, MDNot yet recruiting
- APHP Hôpital Pitié-Salpêtrière - Service de ChirurgieParis, FranceContact: Sébastien Gaujoux, MD PhDNot yet recruiting
- APHP Hôpital R. DebréParis, FranceContact: Elise Bismuth, MDNot yet recruiting
- Aphp-Hopital LariboisiereParis, FranceContact: Jean-François Gautier, MD PhDNot yet recruiting
- Hôpital Pitié-Salpêtrière - Service de DiabétologieParis, FranceContact: Chloé Amouyal, MD PhDNot yet recruiting
- Hopital Rene DubosPontoise, FranceContact: Catherine Campinos, MDNot yet recruiting
About the trial
What the trial wants to find out
National multi-center non-interventional case-control cohort study with collection of biological samples to characterize the autoimmune T and B lymphocytes involved in the development of type 1 diabetes.
The 4 groups in the trial
- Type 1 diabetes
As defined by the presence of hyperglycemia and/or islet auto-antibodies.
Treatment: Biosampling
- Other forms of diabetes or autoimmune endocrinopathy
Type 2 diabetes, ketosis-prone diabetes, familial diabetes, secondary diabetes, immunotherapy-induced diabetes; and/or autoimmune endocrinopathies.
Treatment: Biosampling
- No diabetes
No diabetes or impaired glucose tolerance; no cancer, infectious or immune pathologies; no other condition related to autoimmune and metabolic alterations that may bias the variables under study.
Treatment: Biosampling
- Lymphadenectomy planned at the occasion of an abdominal surgery
Patients undergoing a lymphadenectomy during surgery for the treatment of their underlying pathology.
Treatment: Biosampling
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- BeAT1D: Benign Autoimmunity and Type 1 Diabetes
- Plain-language title
- Immune Cells Studied in Type 1 Diabetes Through Sample CollectionGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 22 May 2026